Literature DB >> 10763190

[Venlafaxine withdrawal syndrome: report of six cases and review of the literature].

V Pinzani1, E Giniès, L Robert, H Peyrière, M Abbar, J P Blayac.   

Abstract

INTRODUCTION: Venlafaxine is an antidepressant that selectively inhibits serotonin reuptake and is a norepinephrine inhibitor. Withdrawal syndromes can occur after abrupt drug discontinuation of long-term regimens. EXEGESIS: We report six cases of withdrawal symptoms after venlafaxine discontinuation.
CONCLUSION: Physicians must be aware of the frequency, rapidity and potent severity of these withdrawal syndromes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10763190     DOI: 10.1016/s0248-8663(00)80048-x

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  4 in total

Review 1.  Venlafaxine and serious withdrawal symptoms: warning to drivers.

Authors:  Daniel M Campagne
Journal:  MedGenMed       Date:  2005-07-06

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

3.  Milnacipran: a unique antidepressant?

Authors:  Siegfried Kasper; Gerald Pail
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

4.  Venlafaxine extended release (XR) in the treatment of panic disorder.

Authors:  Kevin Kjernisted; Diane McIntosh
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.